1. Hematopoietic malignancy (Hodgkin'
Conditions
Interventions
Sponsors
Mie University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Patients aged between 3 and 40 years old at the time of cryopreservation of ovarian tissue and between 18 and 45 years old at the time of ovarian tissue transplantation (transplantation over 45 years is not recomended by the guidelines of the Japanese Society of Reproductive Medicine) 2) Hematopoietic malignancies (Hodgkin's lymphoma, etc.), cervical cancer (squamous cell carcinoma), breast cancer, rare cancers other than hematopoietic malignancies, blood diseases requiring hematopoietic cell transplantation (aplastic anemia, etc.) or autoimmunity Patient diagnosed with the disease 3) Patients judged by the attending physician to have a potential remission of the underlying disease 4) Patients with Performance Status (PS; criteria for establishing the Eastern Cooperative Oncology Group (ECOG)) of 0-1 5) Patients who have been fully informed of the contents of this study using the prescribed consent document and other explanatory documents, and who voluntarily agree to participate in this study in writing Patients who have been obtained) 6) Patients who can undergo ovariectomy within 2 weeks after explanation and consent
Exclusion criteria
Exclusion criteria: 1) Patients with a high probability of metastasis of the original disease to the ovary 2) Patients with obvious infections 3) Patients with severe uncontrollable complications 4) Patients whose doctor judges that this study is inappropriate for participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Birth rate in cryopreserved ovarian tissue autotransplant population | — |
Countries
Japan
Contacts
Public ContactTadashi Maezawa
Mie University Department of Obstetrics and Gynecology, Mie univercity hospital
Outcome results
None listed